We are pleased to announce the start of the PRIME-HF trial (Predischarge Initiation of Ivabradine in the Management of Heart Failure). PRIME-HF is a pragmatic trial that will test the efficacy of initiation of ivabradine prior to discharge from a hospitalization for acute HF compared with usual care. Key endpoints include quality of life, heart rate, beta-blocker use and clinical outcomes through 6 mos. It is a 450-patient study that will begin enrolling soon. Of the 50 sites, we are targeting at >20 DUCCS sites so we can revive the DUCCS vs. SWANs (sites without a name) competition.
We see PRIME-HF as a critical trial to build upon the prior research successes of the DUCCS’ consortium and lay the foundation for future studies.